Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Surgery Partners ( (SGRY) ) is now available.
On August 13, 2025, Surgery Partners, Inc. announced a second amendment to its credit agreement, involving a significant refinancing effort. The amendment introduces a new tranche of term loans totaling $1,383 million, replacing existing loans and revolving credit commitments. This strategic financial restructuring aims to enhance the company’s financial flexibility and operational stability, with the new loans maturing in 2028 and 2030, respectively.
The most recent analyst rating on (SGRY) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Surgery Partners stock, see the SGRY Stock Forecast page.
Spark’s Take on SGRY Stock
According to Spark, TipRanks’ AI Analyst, SGRY is a Neutral.
Surgery Partners shows strong revenue and EBITDA growth, supported by strategic expansions and physician recruitment. However, profitability challenges, high leverage, and valuation concerns weigh on the stock. The technical indicators suggest a lack of strong momentum, while the earnings call provides a balanced outlook with both growth potential and risks.
To see Spark’s full report on SGRY stock, click here.
More about Surgery Partners
Surgery Partners, Inc. operates in the healthcare industry, focusing on providing surgical services. The company manages a network of surgical facilities and offers a range of outpatient and inpatient surgical procedures.
Average Trading Volume: 1,702,788
Technical Sentiment Signal: Sell
Current Market Cap: $2.95B
Find detailed analytics on SGRY stock on TipRanks’ Stock Analysis page.